Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD)

Pathologie Biologie

Volumn 63, Issue 1, 2015, Pages 17-20

  Huang, B ^a   Li, J ^a   Xu, X ^b   Zheng, D ^a   Zhou, Z ^a   Liu, J ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Zhongshan People's Hospital   (China)

Author keywords

Bortezomib; Dexamethasone; Renal light chain amyloidosis

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HEMATOLOGICAL PARAMETERS; HERPES ZOSTER; HUMAN; INFECTION; KIDNEY AMYLOIDOSIS; MALE; MIDDLE AGED; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; RENAL LIGHT CHAIN AMYLOIDOSIS; TREATMENT OUTCOME; AMYLOIDOSIS; KIDNEY DISEASES; RETROSPECTIVE STUDY;

AGED; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DEXAMETHASONE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84922799366     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2014.10.001     Document Type: Article

References (14)

1. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995, 32(1):45-59.
2. Bergesio F., Ciciani A.M., Santostefano M., et al. Renal involvement in systemic amyloidosis-an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant 2007, 22(6):1608-1618.
3. Palladini G., Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 2011, 23(2):214-220.
4. Adams J., Behnke M., Chen S., et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998, 8(4):333-338.
5. Kastritis E., Anagnostopoulos A., Roussou M., et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007, 92(10):1351-1358.
6. Gertz M.A., Comenzo R., Falk R.H., et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22April 2004. Am J Hematol 2005, 79(4):319-328.
7. Bradwell A.R., Carr-Smith H.D., Mead G.P., et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001, 47:673-680.
8. Dimopoulos M.A., Kastritis E. Bortezomib for AL amyloidosis: moving forward. Blood 2011, 118(4):827-828.
9. Gertz M.A., Leung N., Lacy M.Q., et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 2009, 24(10):3132-3137.
10. Sitia R., Palladini G., Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy. Haematologica 2007, 92(10):1302-1307.
11. Kastritis E., Wechalekar A.D., Dimopoulos M.A., et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010, 28(6):1031-1037.
12. Reece D.E., Hegenbart U., Sanchorawala V., et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011, 118(4):865-873.
13. Venner C.P., Lane T., Foard D., et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012, 119(19):4387-4390.
14. Mikhael J.R., Schuster S.R., Jimenez-Zepeda V.H., et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012, 119(19):4391-4394.